Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.62, $0.03 worse than the analyst estimate of $1.65. Revenue for the quarter came in at $145.3 million versus the consensus estimate of $143.54 million.

GUIDANCE:

Collegium Pharma sees FY2024 revenue of $585-595 million, versus the consensus of $605.8 million.Adjusted Operating Expenses (Excluding Stock-Based Compensation): $120.0 to $125.0 million. Adjusted EBITDA (Excluding Stock-Based Compensation): $380.0 to $395.0 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.